Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.79 |
| ▸ | DHODH | Q02127 | 18/20 | 0.78 |
| ▸ | DHFR | P00374 | 1/20 | 0.78 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037307 | 0.92 | DHODH (0.69) | PDE10ADHODHDHFRALKBH5 | |
| SCHEMBL6037352 | 0.90 | DHODH (0.88) | PDE10ADHODHDHFRALKBH5 | |
| SCHEMBL6037303 | 0.89 | DHODH (0.69) | PDE10ADHODHDHFRALKBH5 | |
| SCHEMBL5795268 | 0.89 | PDE10A (1.00) | PDE10ADHODHDHFRALKBH5 | |
| Brequinar SCHEMBL23832490 | 0.88 | DHODH (1.00) | PDE10ADHODHDHFRALKBH5 | |
| Brequinar SCHEMBL29355220 | 0.88 | DHODH (1.00) | PDE10ADHODHDHFRALKBH5 | |
| Brequinar SCHEMBL29688590 | 0.88 | DHODH (1.00) | PDE10ADHODHDHFRALKBH5 | |
| Brequinar SCHEMBL49400 | 0.88 | DHODH (1.00) | PDE10ADHODHDHFRALKBH5 | |
| SCHEMBL6037268 | 0.88 | DHODH (0.83) | PDE10ADHODHDHFRALKBH5 | |
| Brequinar SCHEMBL11906320 | 0.87 | DHODH (0.98) | PDE10ADHODHDHFRALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111368-A1 | Phosphodiesterase inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1541149-A1 | PHOSPHODIESTERASE INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111368-A1 | Phosphodiesterase inhibitor | PDE3A, PDE2A, PDE3B | PDE10A 9/4885DHODH 502/4885DHFR 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.